Recent advances in the genetics of inflammatory bowel disease

Current Opinion in Gastroenterology

Volumn 21, Issue 4, 2005, Pages 401-407

  Newman, Bill ^a   Siminovitch, Katherine A ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Card15; Crohn's disease; Genetic polymorphisms; Inflammatory bowel disease; Linkage analysis

Indexed keywords

BETA CATENIN; CARNITINE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; GAMMA INTERFERON; GUANYLATE KINASE; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MULTIDRUG RESISTANCE PROTEIN 1; MURAMYL DIPEPTIDE; ORGANIC CATION TRANSPORTER; PEPTIDOGLYCAN; PROTEIN DLG5; PROTEIN OCTN1; PROTEIN OCTN2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CHROMOSOME MAP; CROHN DISEASE; DISEASE COURSE; DNA POLYMORPHISM; ENTERITIS; FATTY ACID OXIDATION; GENE EXPRESSION; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HLA SYSTEM; HUMAN; LINKAGE ANALYSIS; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; ULCERATIVE COLITIS;

GENETIC MARKERS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LINKAGE (GENETICS); MEMBRANE PROTEINS; NOD2 SIGNALING ADAPTOR PROTEIN; POLYMORPHISM, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 21844473558     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:182-205.
2. Elson CO. Genes, microbes, and T cells - new therapeutic targets in Crohn's disease. N Engl J Med 2002; 346:614-616.
3. Kirsner JB, Spencer JA. Familial occurrences of ulcerative colitis, region enteritis and ileocolitis. Ann Intern Med 1963; 59:133-144.
4. Mathew CG, Lewis CM. Genetics of inflammatory bowel disease: progress and prospects. Hum Mol Genet 2004; 13:R161-R168.
5. Newman B, Siminovitch K. Inflammatory bowel disease: Crohn's disease and the success of NODern genetics. Clin Invest Med 2003; 26:303-314.
6. Hugot JP, Laurent-Puig P, Gower-Rousseau C, et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996; 379:821-823.
7. Satsangi J, Parkes M, Louis E, et al. Two-stage genome-wide search in inflammatory bowel disease: evidence for susceptiblity loci on chromosomes 3, 7 and 12. Nat Genet 1996; 14:199-202.
8. Cho JH, Nicolae DL, Gold LH, et al. Identification of novel susceptibility loci for inflammatory bowel disease on chromomes 1p, 3q and 4q: evidence for epistasis between 1p and IBD1. Proc Natl Acad Sci USA 1998; 95:7502-7507.
9. Curran ME, Lau KF, Hampe J, et al. Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16. Gastroenterology 1998; 115:1066-1071.
10. Duerr RH, Barmada MM, Zhang L, et al. Linkage and association between inflammatory bowel disease and a locus on chromosome 12. Am J Hum Genet 1998; 63:95-100.
11. Hampe J, Schreiber S, Shaw SH, et al. A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet 1999; 64:808-816.
12. Hampe J, Shaw SH, Saiz R, et al. Linkage of inflammatory bowel disease to human chromosome 6p. Am J Hum Genet 1999; 65:1647-1655.
13. Ma Y, Ohmen JD, Li Z, et al. A genome-wide search identifies potential new susceptibility loci for Crohn's disease. Inflamm Bowel Dis 1999; 5:271-278.
14. Rioux JD, Silverberg MS, Daly MJ, et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet 2000; 66:1863-1870.
15. Duerr RH, Barmada MM, Zhang L, et al. High-density genome scan in Crohn disease shows confirmed linkage to chromosome 14q11-12. Am J Hum Genet 2000; 66:1857-1862.
16. Parkes M, Barmada MM, Satsangi J, et al. The IBD2 locus shows linkage heterogeneity between ulcerative colitis and Crohn disease. Am J Hum Genet 2000; 67:1605-1610.
17. IBD International Genetics Consortium. International collaboration provides convincing linkage replication in complex disease through analysis of a large pooled data set: Crohn disease and chromosome 16. Am J Hum Genet 2001; 68:1165-1171.
18. Hampe J, Lynch NJ, Daniels S, et al. Fine mapping of the chromosome 3p susceptibility locus in inflammatory bowel disease. Gut 2001; 48:191-197.
19. Duerr RH, Barmada MM, Zhang L, et al. Evidence for an inflammatory bowel disease locus on chromosome 3p26: linkage, transmission/disequilibrium and partitioning of linkage. Hum Mol Genet 2002; 11:2599-2606.
20. Williams CN, Kocher K, Lander ES, et al. Using a genome-wide scan and meta-analysis to identify a novel IBD locus and confirm previously identified IBD loci. Inflamm Bowel Dis 2002; 8:375-381.
21. Paavola-Sakki P, Ollikainen V, Helio T, et al. Genome-wide search in Finnish families with inflammatory bowel disease provides evidence for novel susceptibility loci. Eur J Hum Genet 2003; 11:112-120.
22. van Heel D, Dechairo BM, Dawson G, et al. The IBD6 Crohn's disease locus demonstrates complex interactions with CARD15 and IBD5 disease-associated variants. Hum Mol Genet 2003; 12:2569-2575.
23. Barmada MM, Brant SR, Nicolae DL, et al. A genome scan in 260 inflammatory bowel disease-affected relative pairs. Inflamm Bowel Dis 2004; 66: 1863-1870.
24. Vermeire S, Rutgeerts P, Van Steen K, et al. Genome wide scan in a Flemish inflammatory bowel disease population: support for the IBD4 locus, population heterogeneity, and epistasis. Gut 2004; 53:980-986.
25. Pierik M, Yang H, Barmada MM, et al. The IBD international genetics consortium provides further evidence for linkage to IBD4 and shows gene-environment interaction. Inflamm Bowel Dis 2005; 11:1-7.
26. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.
27. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411:603-606.
28. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001; 357:1925-1928.
29. Lesage S, Zouali H, Cezard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002; 70:845-857.
30. Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002; 122:867-874.
31. Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002; 122:854-866.
32. Vermeire S, Wild G, Kocher K, et al. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet 2002; 71:74-83.
33. Bonen DK, Ogura Y, Nicolae DL, et al. Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 2003; 124:140-146.
34. Akolkar PN, Gulvani-Akolkar B, Lin X-Y, et al. The IBD1 locus for susceptibility to Crohn's disease has a greater impact in Ashkenazi Jews with early onset disease. Am J Gastroenterol 2001; 96:1127-1132.
35. Cavanaugh JA, Adams KE, Quak EJ, et al. CARD15/NOD2 risk alleles in the development of Crohn's disease in the Australian population. Ann Hum Genet 2003; 67:35-41.
36. Newman B, Silverberg MS, Gu X, et al. CARD15 and HLA DRB1 alleles influence susceptibility and disease localization in Crohn's disease. Am J Gastroenterol 2004; 99:306-315.
37. Inoue N, Tamura K, Kinouchi Y, et al. Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology 2002; 123:86-91.
38. Sugimura K, Taylor KD, Lin YC, et al. A novel NOD2/CARD15 haplotype conferring risk for Crohn Disease in Ashkenazi Jews. Am J Hum Genet 2003; 72:509-519.
39. Yang H, McElree C, Roth MP, et al. Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut 1993; 34: 517-524.
40. Tukel T, Shalata A, Present D, et al. Crohn Disease: Frequency and Nature of CARD15 Mutations in Ashkenazi and Sephardi/Oriental Jewish Families. Am J Hum Genet 2004; 74:623-636.
41. Karban A, Eliakim R. Failure to replicate the association of the novel NOD2/CARD15 haplotype (S268P-JW1) to Crohn's disease in the Jewish Israeli population. Gastroenterology 2004; 126:624-625.
42. Ogura Y, Inohara N, Benito A. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001; 276:4812-4818.
43. Rosenstiel P, Fantini M, Brautigam K, et al. TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD 15) gene in human intestinal epithelial cells. Gastroenterology 2003; 124:1001-1009.
44. Hisamatsu T, Suzuki M, Reinecker H-C, et al. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003; 124:999-1000.
45. Lala S, Ogura Y, Osborne C. Crohn's disease and the NOD2 gene: a role for paneth cells. Gastroenterology 2003; 125:47-57.
46. Gutierrez O, Pipaon C, Inohara N, et al. Induction of Nod2 in myelomoncytic and intestinal epithelial cells via nuclear factor-κB activation. J Biol Chem 2002; 277:41701-41705.
47. Dang JL, Jones JD. Plant pathogens and integrated defence responses to infection. Nature 2001; 411:826-833.
48. Inohara N, Ogura Y, Nunez G. Nods. A family of cytosolic proteins that regulate the host response to pathogens. Curr Opin Microbiol 2002; 5:76-80.
49. Girardin SE, Sansonetti PJ, Philpott DJ. Intracellular vs extracellular recognition of pathogens - common concepts in mammals and flies. Trends Microbiol 2002; 10:193-199.
50. Medzhitov R, Janeway C. The toll receptor family and microbial recognition. Trends Microbiol 2000; 8:452-456.
51. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003; 85:85-95.
52. Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn's disease. J Biol Chem 2003; 278:5509-5512.
53. Girardin SE, Boneca IG, Viala J, et al. Nod 2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003; 278:8869-8872.
54. Vavricka SR, Musch MW, Chang JE, et al. hPepT1 transports muramyl dipeptide, activating NF-kappaB and stimulating IL-8 secretion in human colonic Caco2/bbe cells. Gastroenterology 2004; 127:1401-1409.
55. Kobayashi KS, Eynon EE, Flavell RA. Intracellular debugging. Nat Immunol 2003; 4:652-654.
56. Inohara N, del Peso L, Koseki T, et al. RICK, a novel protein kinase containing a caspase recruitment domain, interacts with CLARP and regulates CD95-mediated apoptosis. J Biol Chem 1998; 273:12296-12300.
57. Inohara N, Kosecki T, Lin J, et al. An induced proximity model for NF-κB activation in the Nod1/RICK and RIP signaling pathways. J Biol Chem 2000; 275:27823-27831.
58. Kobayashi K, Inohara N, Hernandez LD, et al. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 2002; 416:194-199.
59. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005; 307:731-734. The data in this article reveal CARD15 to be essential for detection of bacterial MDP and reveal impaired induction of intestinal cryptdins/defensins as a possible mechanism whereby CARD15 mutations predispose to CD.
60. Watanabe T, Kitani A, Murray PJ, et al. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 2004; 5:800-808. The data provided in this article provide the first indication of an intersection between toll-like receptor 2 and CARD15 signaling and identify CARD15 inhibition of TLR2 activity as a possible mechanism whereby CARD15 regulates cell responses to bacterial pathogens.
61. Maeda S, Hsu L-C, Liu H, et al. Nod 2 mutation in Crohn's disease potentiates NF-κB activity and IL-Iβ processing. Science 2005; 307:734-738. In this article, mice carrying a germline CARD15 mutant allele are used to demonstrate that CARD15 may act as a positive regulator of NF-κB activation.
62. Uehara A, Yang S, Fujimoto Y, et al. Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocytic cells in culture. Cell Microbiol 2005; 7:53-61.
63. Abbott DW, Wilkins A, Asara JM, et al. The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr Biol 2004; 14:2217-2227.
64. Bevins CL, Martin-Porter E, Ganz T. Defensins and innate host defence of the gastrointestinal tract. Gut 1999; 45:911-915.
65. Wehkamp J, Harder J, Weichenthal M, et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal-defensin expression. Gut 2004; 53:1658-1664.
66. Rioux JD, Daly MJ, Silverberg MS, et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat Genet 2001; 29:223-228.
67. Mirza MM, Fisher SA, King K, et al. Genetic evidence for interaction of the 5q31 cytokine locus and the CARD15 gene in Crohn disease. Am J Hum Genet 2003; 72:1018-1022.
68. Armuzzi A, Ahmad T, Ling KL, et al. Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. Gut 2003; 52:1133-1139.
69. Giallourakis C, Stoll M, Miller K, et al. IBD5 is a general risk factor for inflammatory bowel disease: replication of association with Crohn disease and identification of a novel association with ulcerative colitis. Am J Hum Genet 2003; 73:205-211.
70. Negoro K, McGovern DP, Kinouchi Y, et al. Analysis of the IBD5 locus and potential gene-gene interactions in Crohn's disease. Gut 2003; 52:541-546.
71. Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation transporter genes are associated with Crohn's Disease. Nat Genet 2004; 36:471-475. This article reports on the discovery of gene variants in the SLC22A4 and SLC22A5 genes that are associated with Crohn disease, impair function/expression of the OCTN1 and OCTN2 transporters encoded by these genes, and interact with CARD15 variants to confer risk for CD.
72. Yabuuchi H, Tamai I, Nezu J, et al. Novel membrane transporter OCTN1 mediates multispecific, bidirectional and pH-dependent transport of organic cations. J Pharmacol Exp Ther 1999; 289:768-773.
73. Oshashi R, Tamai I, Nezu J, et al. A molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol 2001; 59:358-366.
74. Burckhardt G, Wolff NA. Structure of renal organic anion and cation transporters. Am J Physiol Renal Physiol 2000; 278:F853-F866.
75. Newman B, Gu X, Wintle RF, et al. A risk haplotype in the solute carrier family 22A4/22A5 gene cluster influences phenotypic expression of Crohn's disease. Gastroenterology 2005; 128:260-269.
76. Yamazaki K, Takazoe M, Tanaka T, et al. Association analysis of SLC22A4, SLC22A5 and DLG5 in Japanese patients with Crohn disease. J Hum Genet 2004; 49:664-668.
77. Tokuhiro S, Yamada R, Chang X, et al. An intronic SNP in a RUNXI binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet 2003; 35:341-348.
78. Newman B, Wintle RF, van Oene M, et al. SLC22A4 polymorphisms implicated in rheumatoid arthritis and Crohn's disease are not associated with rheumatoid arthritis in a Canadian Caucasian population. Arthritis Rheum 2005; 52:425-429.
79. Lahjouji K, Mitchell GA, Qureshi IA. Carnitine transport by organic cation transporters and systemic carnitine deficiency. Mol Genet Metab 2001; 73:287-297.
80. Roediger WE, Nance S. Metabolic induction of experimental ulcerative colitis by inhibition of fatty acid oxidation. Br J Exp Pathol 1986; 67:773-782.
81. Stoll M, Corneliussen B, Costello CM, et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet 2004; 36:476-480. In this article, linkage disequilibrium mapping is used successfully to identify DLG5 variants as susceptibility alleles for IBD.
82. Nakamura H, Sudo T, Tsuiki H, et al. Identification of a novel human homolog of the Drosophila dig, P-dlg, specifically expressed in the gland tissues and interacting with p55. FEBS Lett 1998; 433:63-67.
83. Shah G, Brugada R, Gonzalez O, et al. The cloning, genomic organization and tissue expression profile of the human DLG5 gene. BMC Genomics 2002; 3:6.
84. Wakabayashi M, Ito T, Mitsushima M, et al. Interaction of lp-dlg/KIAA0583, a membrane-associated guanylate kinase family protein, with vinexin and beta-catenin at sites of cell-cell contact. J Biol Chem 2003; 278:21709-21714.
85. Hollander D. Crohn's disease - a permeability disorder of the tight junction? Gut 1988; 29:1621.
86. Olaison G, Sjodahl R, Tagesson C, et al. Abnormal intestinal permeability in Crohn's disease. A possible pathogenic factor. Scand J Gastroenterol 1990; 25:321-328.
87. May G, Sutherland L, Meddings JB. Is small intestinal permeability really increased in relatives of patients with Crohn's disease? Gastroenterology 1993; 104:1627-1632.
88. Peeters M, Geypens B, Claus D. Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology 1997; 113: 802-807.
89. van Heel DA, Fisher SA, Kirby A, et al. Inflammatory bowel disease susceptibility loci defined by genome scan meta-analysis of 1952 affected relative pairs. Hum Mol Genet 2004; 13:763-770. In this study, a meta-analysis of available IBD genome-wide screens is used to prioritize IBD loci meriting further genetic analysis and to identify several previously undetected susceptibility loci.
90. Jones PM, George AM. A new structural model for P-glycoprotein. J Membr Biol 1998; 166:133-147.
91. Fojo AT, Ueda K, Slamon D, et al. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84:265-269.
92. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998; 161:5733-5774.
93. Schwab M, Schaeffeler E, Marx C, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003; 124:26-33.
94. Ho G, Nimmo E, Tanesa A, et al. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology 2005; 128:288-296.
95. Brant SR, Panhuysen CI, Nicolae D, et al. MDR1 Ala893 Polymorphism is Associated with Inflammatory Bowel Disease. Am J Hum Genet 2003; 73:1282-1292.
96. Croucher PJ, Mascheretti S, Foelsch UR, et al. Lack of association between the C3435T MDR1 gene polymorphism and inflammatory bowel disease in two independent Northern European populations. Gastroenterology 2003; 125:1919-1920.
97. Glas J, Torok HP, Schiemann U, Folwaczny C. MDR1 gene polymorphism in ulcerative colitis. Gastroenterology 2004; 126:367.
98. Gazouli M, Zacharatos P, Gorgoulis V, et al. The C3435T MDR1 gene polymorphism is not associated with susceptibility for ulcerative colitis in Greek population. Gastroenterology 2004; 126:367-369.
99. Hubbard AK, Rothlein R. Intercellular adhesion molecule-1 (ICAM-1) expression and cell signalling cascades. Free Radio Biol Med 2000; 28:1379-1386.
100. Yang H, Vora DK, Targan SR, et al. Intercellular adhesion molecule 1 gene associations with immunologic subsets of inflammatory bowel disease. Gastroenterology 1995; 109:440-448.
101. Yang H. Analysis of ICAM-1 gene polymorphism in immunologie subsets of inflammatory bowel disease. Exp Clin Immunogenet 1997; 14:214-225.
102. Braun C, Zahn R, Martin K, et al. Polymorphisms of the ICAM-1 gene are associated with inflammatory bowel disease, regardless of the p-ANCA status. Clin Immunol 2001; 101:357-360.
103. Neville MJ, Dechairo BM, Walton R, et al. Inflammatory bowel disease is linked to 19p13 and associated with ICAM-1. Inflamm Bowel Dis 2004; 10:173-181.
104. Stokkers PC, Reitsma PH, Tytgat GN, et al. HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut 1999; 45:395-401.
105. Silverberg MS, Mirea L, Bull SB, et al. A population and family-based study of Canadian families reveals association of HLA DRB 1*0103 with colonic involvement in inflammatory bowel disease. Inflamm Bowel Dis 2003; 9:1-9.
106. Yap LM, Ahmad T, Jewell DP. The contribution of HLA genes to IBD susceptibility and phenotype. Best Pract Res Clin Gastroenterol 2004; 18: 577-596.
107. De La Concha EG, Fernandrez-Arquero M, Lopez-Nava G, et al. Susceptibility to severe ulcerative colitis is associated with polymorphism in the central MHC gene IKBL. Gastroenterology 2000; 119:1491-1495.
108. van Heel DA, Udalova IA, De Silva AP, et al. Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between OCT1 and NF-κB transcription factors. Hum Mol Genet 2002; 11:1281-1289.
109. Rachmilewitz D, Katakura K, Karmeli F, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004; 126:520-528.
110. Torok HP, Glas J, Tonenchi L, et al. Crohn's disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology 2004; 127:365-366.
111. Karban AS, Okazaki T, Panhuysen CI, et al. Functional annotation of a novel NFKB1 promoter Polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004; 13:35-45.